Novaccess Global Inc. has announced the approval of its application with the FDA for orphan drug designation for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. The company’s therapeutic path involves a unique transformational process, which involves the addition of proprietary substances to create a cocktail for more personalized treatment that substantially increases clinical benefits for patients.
P-glycoprotein (P-gp) is a multidrug resistance (MDR)-associated protein, which is widely distributed in membranes of several cells including hepatocytes, renal proximal tubular cells and brain capillary endothelial cells. The overexpression of this drug efflux transporter protein is considered to play a key role in the development of MDR.
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana. For Vivek Subbiah, associate professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine of the MD Anderson Cancer Center, the story of how Rama defeated Ravana has parallels in drug discovery. Ravana had 10 heads, and when one was cut off, it grew back. Rama defeated Ravana by means of a magic arrow that entered through the demon’s navel.
Ono Pharmaceutical Co. Ltd. has disclosed monoacylglycerol lipase ABHD6 inhibitors reported to be useful for the treatment of cancer, pain, neurological, inflammatory, autoimmune and metabolic diseases.
Acerand Therapeutics (USA) Ltd. has discovered new son of sevenless homologue 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Nimbus Saturn Inc. has presented mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer and viral infections.
Blueprint Medicines Corp. has synthesized new diazepanone-fused pyrimidines acting as epidermal growth factor receptor (EGFR) (mutant) and/or HER2 (mutant) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, eczema and psoriasis.
Researchers from Qualigen Therapeutics Inc. and University of Louisville presented the discovery and preclinical evaluation of a novel pan-RAS inhibitor...
Haisco Pharmaceutical Group Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
RSS
